Recombinant interleukin-2 and the quest for FDA approval.
作者信息
Tami J A
出版信息
Clin Pharm. 1991 Feb;10(2):141-2.
PMID:2009733
Abstract
摘要
相似文献
1
Recombinant interleukin-2 and the quest for FDA approval.重组白细胞介素-2与寻求美国食品药品监督管理局批准
Clin Pharm. 1991 Feb;10(2):141-2.
2
Interleukin-2.白细胞介素-2
Med Lett Drugs Ther. 1987 Sep 25;29(749):88-9.
3
IL-2 therapy proves durable in renal cell melanoma patients.
Oncology (Williston Park). 1991 Sep;5(9):71.
4
[Bacteremia caused by Streptococcus equisimilis in a neoplastic patient treated with recombinant interleukin 2].[重组白细胞介素2治疗的肿瘤患者中马链球菌似马亚种引起的菌血症]
Enferm Infecc Microbiol Clin. 1990 Dec;8(10):659-60.
5
6
Keynote address: perspectives on the use of interleukin-2 in cancer treatment.主题演讲：白细胞介素-2在癌症治疗中的应用前景
Cancer J Sci Am. 1997 Dec;3 Suppl 1:S2-6.
7
8
Combination biologic therapy with interleukin-2 and interferon-alfa in the outpatient treatment of metastatic renal cell carcinoma.白细胞介素-2与α干扰素联合生物疗法用于转移性肾细胞癌的门诊治疗
Semin Oncol. 1993 Dec;20(6 Suppl 9):11-5.
9
Role of interleukin-2 alone in disseminated renal cell carcinoma: an update.单独使用白细胞介素-2在转移性肾细胞癌中的作用：最新进展
Prog Clin Biol Res. 1989;303:671-9.
10
Phase I clinical trial of interleukin 2 and alpha-interferon: toxicity and immunologic effects.白细胞介素2与α干扰素的I期临床试验：毒性及免疫效应
Cancer Res. 1989 Nov 15;49(22):6432-6.
Zotero 插件